Abstract 36P
Background
Checkpoint inhibition(CPI) by antibodies against PD-1, CTLA-4 and other immunoinhibitors has revolutionized cancer treatment. However, there are limited data on CPIs that target the activation phase of adaptive immune responses. Signaling through the immunoinhibitory B and T lymphocyte attenuator (BTLA), upon binding to the herpes virus entry mediator (HVEM) on dendritic cells, regulates early steps of CD8+ T cell activation. HSV-1 glycoprotein D (gD) attaches to HVEM and blocks BTLA-HVEM signaling and allows for co-stimulation through LIGHT, which binds to a different domain on HVEM. BTLA blockade, in turn, enhances and broadens CD8+ T cell responses to a target antigen. Here, we report the immunogenicity and efficacy of a chimpanzee adenoviral vector (AdC) vaccine expressing a novel sequence derived from the early proteins 2, 5, 6 and 7 of HPV-16 fused into gD (AdC-gDE7652).
Methods
The frequency of HPV-16-specific CD8+ T-cells was assessed with intracellular cytokine staining in C57/Bl6 or HLA-A2 mice after a single IM vaccination with AdC vectors encoding HPV-16 E7652 oncoproteins expressed within gD or without gD. Efficacy was tested in a standard (5x10ˆ4 cells) dose TC-1 tumor cell challenge model with mice receiving a single IM injection of AdC-gDE7652 or AdC expressing HIV gag fused within gD (AdC-gDgag) 3 days after tumor cell transplantation. Mice were followed for 80 days.
Results
The addition of gD increased HPV-16 -specific CD8+ T-cell frequencies approximately 15-fold. In the standard TC-1 challenge experiment, 100% (n = 10) of the AdC-gDE7652 vaccinated animals experienced regression and complete tumor loss by day 25; this was sustained through day 80. In contrast, 100% (n=10) of the AdC-gDgag vaccinated animals experienced rapid tumor growth and death by day 21.
Conclusions
These preclinical data demonstrated that the addition of gD, an early checkpoint modifier, which acts locally at the site of T cell stimulation, to an HPV-16 vaccine markedly improves the vaccine’s immunogenicity and efficacy. A clinical study evaluating this construct, in HPV-16 induced cancers and precancerous lesions, is in development.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Virion Therapeutics Llc.
Disclosure
S.L. Currie: Financial Interests, Personal, Stocks/Shares: Virion Therapeutics. A. Luber: Financial Interests, Personal, Ownership Interest: Virion Therapeutics. H.C. Ertl: Other, Personal and Institutional, Leadership Role, Co-founder: Virion Therapeutics; Other, Personal, Advisory Role: Biogen, Regenxbio; Other, Personal, Advisory Board: Ring Therapeutics, Canine Rabies Treatment Initiative. All other authors have declared no conflicts of interest.
Resources from the same session
40P - Development of radiolabelled plerixafor as a theranostic molecule for targeting CXCR4 receptor expressing cancers: A translational study
Presenter: Tamanna Lakhanpal
Session: Cocktail & Poster Display session
Resources:
Abstract
41P - BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
Presenter: Beatriz Alonso de Castro
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Prognostic impact of the tumor immune microenvironment in adrenocortical cancer
Presenter: Nano Pachuashvili
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy
Presenter: Lauren Wood
Session: Cocktail & Poster Display session
Resources:
Abstract
45P - Discovery of CBO-212, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer
Presenter: James Levin
Session: Cocktail & Poster Display session
Resources:
Abstract
48P - Efficacy analysis and mechanism exploration of furmonertinib for advanced NSCLC with EGFR exon 20 insertion mutation
Presenter: Xiao Zhang
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Treatment management in RAS and BRAF mutations in patients with metastatic colorectal cancer
Presenter: Merve Özkan
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - KRAS mutation, the molecular landscape of lung adenocarcinoma in the Portuguese population
Presenter: Carolina Trabulo
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit
Presenter: Katerin Rojas Laimito
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - Antitumor efficacy of polypyrrole-polyethyleneimine nanocomplex to target B-cell lymphoma
Presenter: Thi Thuy Nguyen
Session: Cocktail & Poster Display session
Resources:
Abstract